NAFL
MCID: NNL005
MIFTS: 61

Non-Alcoholic Fatty Liver Disease (NAFL)

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Non-Alcoholic Fatty Liver Disease

MalaCards integrated aliases for Non-Alcoholic Fatty Liver Disease:

Name: Non-Alcoholic Fatty Liver Disease 12 25 15 17
Nonalcoholic Fatty Liver Disease 25 36 15
Non-Alcoholic Fatty Liver 12 15 17
Fatty Liver 25 54
Steatosis 25 17
Nafld 12 25
Susceptibility to Nonalcoholic Fatty Liver Disease 6
Non-Alcoholic Steatohepatitis 25
Nonalcoholic Steatohepatitis 25
Nafl 12
Nash 25

Classifications:



External Ids:

Disease Ontology 12 DOID:0080208 DOID:0080546
KEGG 36 H01333

Summaries for Non-Alcoholic Fatty Liver Disease

Genetics Home Reference : 25 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat. The fat deposits in the liver associated with NAFLD usually cause no symptoms, although they may cause increased levels of liver enzymes that are detected in routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged. Between 7 and 30 percent of people with NAFLD develop inflammation of the liver (non-alcoholic steatohepatitis, also known as NASH), leading to liver damage. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue (fibrosis), resulting in irreversible liver disease (cirrhosis) that causes the liver to stop working properly. Signs and symptoms of cirrhosis, which get worse as fibrosis affects more of the liver, include fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), and yellowing of the skin and whites of the eyes (jaundice). Scarring in the vein that carries blood into the liver from the other digestive organs (the portal vein) can lead to increased pressure in that blood vessel (portal hypertension), resulting in swollen blood vessels (varices) within the digestive system. Rupture of these varices can cause life-threatening bleeding. NAFLD and NASH are thought to account for many cases of cirrhosis that have no obvious underlying cause (cryptogenic cirrhosis); at least one-third of people with NASH eventually develop cirrhosis. People with NAFLD, NASH, and cirrhosis are also at increased risk of developing liver cancer (hepatocellular cancer). NAFLD is most common in middle-aged or older people, although younger people, including children, are also affected. It is often considered as part of a group of conditions known collectively as the metabolic syndrome; in addition to NAFLD, the metabolic syndrome includes obesity, type 2 diabetes or pre-diabetes (insulin resistance), high levels of fats (lipids) such as cholesterol and triglycerides in the blood, and high blood pressure (hypertension). However, a person with NAFLD may not have all or any of the other conditions that make up the metabolic syndrome, and individuals with some or all of those conditions may not have NAFLD.

MalaCards based summary : Non-Alcoholic Fatty Liver Disease, also known as nonalcoholic fatty liver disease, is related to non-alcoholic steatohepatitis and lipid metabolism disorder. An important gene associated with Non-Alcoholic Fatty Liver Disease is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Non-alcoholic fatty liver disease (NAFLD) and Glycerolipid metabolism. The drugs Losartan and Milk thistle have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart.

Disease Ontology : 12 A fatty liver disease characterized by the storing of excess fat in liver cells which is not caused by heavy alcohol use.

KEGG : 36 It has been reported that those patients with nonalcoholic fatty liver disease (NAFLD) are probably more common in those individuals with metabolic syndrome, which includes obesity and type 2 diabetes mellitus. The spectrum of NAFLD ranges from simple steatosis to steatohepatitis with hepatic inflammation and fibrosis, known as nonalcoholic steatohepatitis (NASH). Of those with NASH, approximately 20% will go on to develop cirrhosis and hepatocellular carcinoma.

Related Diseases for Non-Alcoholic Fatty Liver Disease

Diseases related to Non-Alcoholic Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 889)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic steatohepatitis 34.3 MIR34A MIR21 MIR122
2 lipid metabolism disorder 32.2 MIR33A MIR21 MIR122
3 psoriasis 31.4 MIR31 MIR22 MIR21 MIR200A MIR122
4 body mass index quantitative trait locus 11 31.3 MIR378A MIR34A MIR27B MIR27A MIR22 MIR21
5 overnutrition 31.1 MIR378A MIR34A MIR27B MIR27A MIR22 MIR21
6 arteries, anomalies of 31.1 MIR34A MIR33A MIR29C MIR27B MIR27A MIR22
7 inherited metabolic disorder 30.8 MIR34A MIR21 MIR122
8 hepatocellular carcinoma 30.8 MIR34A MIR33A MIR31 MIR29C MIR27A MIR26A1
9 renal fibrosis 30.7 MIR29C MIR21 MIR200B
10 acquired metabolic disease 30.6 MIR378A MIR27B MIR27A MIR22 MIR21 MIR200A
11 lipid storage disease 30.6 MIR22 MIR21 MIR122
12 glucose metabolism disease 30.3 MIR378A MIR27A MIR22 MIR21 MIR140
13 bile duct adenocarcinoma 30.3 MIR31 MIR21 MIR140
14 muscular dystrophy, duchenne type 30.3 MIR34A MIR29C MIR22 MIR21
15 intestinal disease 30.2 MIR378A MIR34A MIR31 MIR29C MIR27B MIR22
16 lymphoma, hodgkin, classic 30.2 MIR21 MIR200A MIR140
17 pancreatic cancer 30.2 MIR34A MIR31 MIR27A MIR21 MIR200A MIR183
18 rectum cancer 30.1 MIR31 MIR21 MIR200A
19 ovarian disease 30.1 MIR27A MIR22 MIR21 MIR200B MIR200A MIR140
20 lymphoma, non-hodgkin, familial 30.0 MIR34A MIR31 MIR27A MIR21 MIR200B MIR140
21 gastric cancer 30.0 MIR34A MIR31 MIR29C MIR27B MIR27A MIR22
22 kidney cancer 30.0 MIR378A MIR29C MIR27A MIR21 MIR200B MIR122
23 bladder cancer 29.9 MIR34A MIR31 MIR29C MIR21 MIR200A MIR10B
24 colorectal cancer 29.9 MIR34A MIR31 MIR29C MIR27B MIR27A MIR26A1
25 prostate disease 29.9 MIR34A MIR31 MIR27A MIR22 MIR21 MIR200B
26 esophageal cancer 29.7 MIR34A MIR31 MIR27A MIR21 MIR200A MIR183
27 prostate cancer 29.7 MSR1 MIR34A MIR31 MIR27B MIR27A MIR22
28 lung cancer susceptibility 3 29.6 MIR31 MIR29C MIR27A MIR21 MIR200B MIR200A
29 pancreas disease 29.5 MIR34A MIR33A MIR31 MIR27B MIR27A MIR22
30 breast cancer 29.4 MSR1 MIR34A MIR31 MIR29C MIR27A MIR22
31 lung cancer 29.3 MIR378A MIR34A MIR33A MIR31 MIR29C MIR27B
32 ovarian cancer 29.2 MIR34A MIR31 MIR29C MIR27A MIR22 MIR21
33 gastrointestinal system disease 28.9 MIR378A MIR34A MIR33A MIR31 MIR29C MIR27B
34 fatty liver disease, nonalcoholic 2 12.6
35 fatty liver disease, nonalcoholic 1 12.5
36 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 12.4
37 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.2
38 hypertriglyceridemia, transient infantile 12.1
39 lipodystrophy, familial partial, type 2 11.9
40 liver disease 11.8
41 fatty liver disease 11.8
42 reye syndrome 11.7
43 congenital generalized lipodystrophy 11.4
44 familial partial lipodystrophy 11.4
45 mitochondrial dna depletion syndrome 4a 11.4
46 adrenomyodystrophy 11.4
47 visceral steatosis, congenital 11.4
48 corticosteroid-binding globulin deficiency 11.2
49 lipodystrophy, congenital generalized, type 2 11.2
50 3-methylglutaconic aciduria, type v 11.2

Graphical network of the top 20 diseases related to Non-Alcoholic Fatty Liver Disease:



Diseases related to Non-Alcoholic Fatty Liver Disease

Symptoms & Phenotypes for Non-Alcoholic Fatty Liver Disease

Drugs & Therapeutics for Non-Alcoholic Fatty Liver Disease

Drugs for Non-Alcoholic Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 473)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Losartan Approved Phase 4 114798-26-4 3961
2
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
5
Insulin glulisine Approved Phase 4 207748-29-6
6
Liraglutide Approved Phase 4 204656-20-2 44147092
7
Glucagon Approved Phase 4 16941-32-5
8
Insulin aspart Approved Phase 4 116094-23-6 16132418
9
Insulin detemir Approved Phase 4 169148-63-4 5311023
10
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
11
Gliclazide Approved Phase 4 21187-98-4 3475
12
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
13
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
14
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
17
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
18
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
19
Tamoxifen Approved Phase 4 10540-29-1 2733526
20
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
21
Ergotamine Approved Phase 4 113-15-5 8223
22
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
23
Nortriptyline Approved Phase 4 72-69-5 4543
24
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
25
Zidovudine Approved Phase 4 30516-87-1 35370
26
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
27
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
28
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
29
Glimepiride Approved Phase 4 93479-97-1 3476
30
Aminolevulinic acid Approved Phase 4 106-60-5 137
31
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
32
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
33
tannic acid Approved Phase 4 1401-55-4
34
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
35
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
36
Lenvatinib Approved, Investigational Phase 4 417716-92-8
37
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
38
Methyltestosterone Approved Phase 4 58-18-4 6010
39
Testosterone enanthate Approved Phase 4 315-37-7 9416
40
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
41
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
42
Empagliflozin Approved Phase 4 864070-44-0
43
Dulaglutide Approved, Investigational Phase 4 923950-08-7
44
Alogliptin Approved Phase 4 850649-61-5 11450633
45
Metformin Approved Phase 4 657-24-9 14219 4091
46
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
47
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
48
Zinc Approved, Investigational Phase 4 7440-66-6 32051
49
Insulin glargine Approved Phase 4 160337-95-1
50
Saxagliptin Approved Phase 4 361442-04-8 11243969

Interventional clinical trials:

(show top 50) (show all 1423)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
3 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
4 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
5 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
6 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
7 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
8 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
9 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
10 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
11 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
12 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
13 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
14 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
15 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
16 Treatment by Subcutaneous Continuous Infusion of Insulin by Portable Pump Versus Discontinuous Infusion of Insulin by Multi-injections in the Type 2 Diabetes: Study of the Insulinosensibility in the 2 Types of Treatments Unknown status NCT01889914 Phase 4 2 different procedures of administration of insulin
17 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
18 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
19 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
20 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
21 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
22 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
23 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
24 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
25 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
26 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
27 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
28 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
29 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
30 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
31 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
32 Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus Completed NCT01951651 Phase 4 Exenatide;Glipizide
33 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
34 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
35 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
36 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
37 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
38 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
39 Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus Completed NCT01432405 Phase 4 Exenatide;Pioglitazone
40 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
41 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
42 Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component Completed NCT03374358 Phase 4 Raltegravir
43 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
44 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
45 Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome Completed NCT01356394 Phase 4
46 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
47 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
48 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
49 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
50 A 24 Week Monocentric Prospective Randomized, Placebo-controlled Trial to Evaluate Efficacy of Combination of Exenatide and Dapagliflozin Compared to Dapagliflozin and Placebo and Its Effects on Hepatic, Myocardial and Pancreatic Fat Distribution in Patients With Uncontrolled Type 2 Diabetes Mellitus. Completed NCT03007329 Phase 4 Exenatide;Exenatide matching Placebo;Dapagliflozin

Search NIH Clinical Center for Non-Alcoholic Fatty Liver Disease

Genetic Tests for Non-Alcoholic Fatty Liver Disease

Anatomical Context for Non-Alcoholic Fatty Liver Disease

MalaCards organs/tissues related to Non-Alcoholic Fatty Liver Disease:

40
Liver, Testes, Heart, Kidney, Endothelial, Ovary, Thyroid

Publications for Non-Alcoholic Fatty Liver Disease

Articles related to Non-Alcoholic Fatty Liver Disease:

(show top 50) (show all 17725)
# Title Authors PMID Year
1
Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. 61 46
20956972 2011
2
Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. 46 61
20497147 2010
3
Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. 61 46
19780876 2010
4
Transplantation of brown adipose tissue up-regulates miR-99a to ameliorate liver metabolic disorders in diabetic mice by targeting NOX4. 61
32000567 2020
5
Herbal formulation MIT ameliorates high-fat diet-induced non-alcoholic fatty liver disease. 61
32489856 2020
6
Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease. 61
31852298 2020
7
GSK-3 in liver diseases: Friend or foe? 61
32417256 2020
8
Ginsenoside Mc1 improves liver steatosis and insulin resistance by attenuating ER stress. 61
32387461 2020
9
Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription. 61
32438122 2020
10
Lipocalin-type prostaglandin D2 synthase deletion induces dyslipidemia and non-alcoholic fatty liver disease. 61
32145387 2020
11
PBPK modeling of impact of nonalcoholic fatty liver disease on toxicokinetics of perchloroethylene in mice. 61
32445755 2020
12
CREBH knockout accelerates hepatic fibrosis in mouse models of diet-induced nonalcoholic fatty liver disease. 61
32417373 2020
13
The influence of probiotics on bile acids in diseases and aging. 61
32504921 2020
14
Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway. 61
32521450 2020
15
Sodium acetate-mediated inhibition of histone deacetylase alleviates hepatic lipid dysregulation and its accompanied injury in streptozotocin-nicotinamide-induced diabetic rats. 61
32460191 2020
16
Cathepsin B deficiency ameliorates liver lipid deposition, inflammatory cell infiltration, and fibrosis after diet-induced nonalcoholic steatohepatitis. 61
32434697 2020
17
TLR4 knockout upregulates the expression of Mfn2 and PGC-1α in a high-fat diet and ischemia-reperfusion mice model of liver injury. 61
32437795 2020
18
Exposure to 2,3,3',4,4',5-hexachlorobiphenyl promotes nonalcoholic fatty liver disease development in C57BL/6 mice. 61
32304952 2020
19
Gan-Jiang-Ling-Zhu decoction alleviates hepatic steatosis in rats by the miR-138-5p/CPT1B axis. 61
32325349 2020
20
Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis. 61
32388250 2020
21
2,3,5,4'-tetrahydroxystilbence-2-O-β-D-glucoside attenuates hepatic steatosis via IKKβ/NF-κB and Keap1-Nrf2 pathways in larval zebrafish. 61
32387861 2020
22
Adipose tissue-liver crosstalk during pathologic changes caused by vinyl chloride metabolites in mice. 61
32445754 2020
23
Capsaicinoid nonivamide improves nonalcoholic fatty liver disease in rats fed a high-fat diet. 61
32414691 2020
24
Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent. 61
32271385 2020
25
Potential role of gut microbiota, the proto-oncogene PIKE (Agap2) and cytochrome P450 CYP2W1 in promotion of liver cancer by alcoholic and nonalcoholic fatty liver disease and protection by dietary soy protein. 61
32417163 2020
26
COX-2 in liver fibrosis. 61
32184095 2020
27
Advances in non-invasive assessment of hepatic fibrosis. 61
32066623 2020
28
Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard. 61
31843596 2020
29
Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease". 61
32265051 2020
30
FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease. 61
32276730 2020
31
Effects of a carbohydrate-restricted diet on hepatic lipid content in adolescents with non-alcoholic fatty liver disease: A pilot, randomized trial. 61
32128995 2020
32
Heme oxygenase-1 alleviated non-alcoholic fatty liver disease via suppressing ROS-dependent endoplasmic reticulum stress. 61
32376267 2020
33
Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. 61
32124081 2020
34
Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease. 61
32229037 2020
35
Caveats for the implementation of global strategies against non-alcoholic fatty liver disease. 61
32229039 2020
36
Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease". 61
32280051 2020
37
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment. 61
32339855 2020
38
ApoE deficiency promotes non-alcoholic fatty liver disease in mice via impeding AMPK/mTOR mediated autophagy. 61
32304762 2020
39
Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation. 61
32279432 2020
40
Childhood obesity and adult non-alcoholic fatty liver disease. 61
32064764 2020
41
Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome. 61
31714387 2020
42
Identification and Characterization of Nonalcoholic Fatty Liver Disease. 61
31404663 2020
43
Increasing Liver Fat Is Associated With Incident Cardiovascular Risk Factors. 61
31404666 2020
44
Alcohol Use Is Associated With Hepatic Steatosis Among Persons With Presumed Nonalcoholic Fatty Liver Disease. 61
31734449 2020
45
Maternal sucralose intake alters gut microbiota of offspring and exacerbates hepatic steatosis in adulthood. 61
32228300 2020
46
Ling-gui-zhu-gan decoction alleviates hepatic steatosis through SOCS2 modification by N6-methyladenosine. 61
32559839 2020
47
Oxygen therapy alleviates hepatic steatosis by inhibiting hypoxia-inducible factor-2α. 61
32369776 2020
48
Bariatric Surgery Decreases the Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis. 61
32559048 2020
49
The Emerging Epidemic of Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: True, True, and Related? 61
32026275 2020
50
[New pharmacological treatment options for nonalcoholic fatty liver disease]. 61
32409850 2020

Variations for Non-Alcoholic Fatty Liver Disease

ClinVar genetic disease variations for Non-Alcoholic Fatty Liver Disease:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PNPLA3 NM_025225.3(PNPLA3):c.*987_*989dupduplication Uncertain significance 341961 rs3083314 22:44343239-44343240 22:43947359-43947360
2 PNPLA3 NM_025225.3(PNPLA3):c.*989dupduplication Uncertain significance 341959 rs3083314 22:44343239-44343240 22:43947359-43947360
3 PNPLA3 NM_025225.3(PNPLA3):c.*691_*692dupduplication Likely benign 341954 rs397716964 22:44342941-44342942 22:43947061-43947062
4 PNPLA3 NM_025225.3(PNPLA3):c.*988_*989dupduplication Likely benign 341960 rs3083314 22:44343239-44343240 22:43947359-43947360

Cosmic variations for Non-Alcoholic Fatty Liver Disease:

9 (show top 50) (show all 15626)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 27
2 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 27
3 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 27
4 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 27
5 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 27
6 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 27
7 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 27
8 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 27
9 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 27
10 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 27
11 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 27
12 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 27
13 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 27
14 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 27
15 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 27
16 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 27
17 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 27
18 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 27
19 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 27
20 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 27
21 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 27
22 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 27
23 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 27
24 COSM92703312 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 27
25 COSM92032561 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221= 14:67807621-67807621 27
26 COSM84360265 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.1979+14C>A p.? 5:32395145-32395145 27
27 COSM84362097 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 27
28 COSM85178149 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 27
29 COSM87884183 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 27
30 COSM127392053 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 27
31 COSM149268658 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 27
32 COSM149328017 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 27
33 COSM149281099 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 27
34 COSM144309108 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 27
35 COSM87420403 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 27
36 COSM98996636 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 27
37 COSM92255466 ZC3H15 liver,NS,carcinoma,hepatocellular carcinoma c.*55T>G p.? 2:186508788-186508788 27
38 COSM85044193 ZC3H14 liver,NS,carcinoma,hepatocellular carcinoma c.*10873G>A p.? 14:88622624-88622624 27
39 COSM106743522 ZBTB7B liver,NS,carcinoma,hepatocellular carcinoma c.*635G>C p.? 1:155017320-155017320 27
40 COSM93795261 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 27
41 COSM103188148 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 27
42 COSM91488114 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 27
43 COSM95291738 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 27
44 COSM107993551 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2383A>G p.I795V 8:80519295-80519295 27
45 COSM107993152 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2208A>G p.T736= 8:80518852-80518852 27
46 COSM86073785 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 27
47 COSM142300159 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1580A>G p.N527S 8:63187582-63187582 27
48 COSM90849676 YOD1 liver,NS,carcinoma,hepatocellular carcinoma c.*157T>C p.? 1:207048863-207048863 27
49 COSM90620829 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 27
50 COSM86902201 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167= 3:183722100-183722100 27

Expression for Non-Alcoholic Fatty Liver Disease

Search GEO for disease gene expression data for Non-Alcoholic Fatty Liver Disease.

Pathways for Non-Alcoholic Fatty Liver Disease

Pathways related to Non-Alcoholic Fatty Liver Disease according to KEGG:

36
# Name Kegg Source Accession
1 Non-alcoholic fatty liver disease (NAFLD) hsa04932
2 Glycerolipid metabolism hsa00561

Pathways related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 MIR34A MIR31 MIR29C MIR27B MIR27A MIR26A1

GO Terms for Non-Alcoholic Fatty Liver Disease

Cellular components related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 MIR378A MIR31 MIR29C MIR27B MIR27A MIR26A1
2 extracellular vesicle GO:1903561 9.23 MIR34A MIR29C MIR27B MIR27A MIR26A1 MIR22

Biological processes related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.02 MIR132 MIR140 MIR21 MIR27B MIR34A
2 negative regulation of cell migration GO:0030336 9.88 MIR21 MIR26A1 MIR29C MIR34A
3 negative regulation of gene expression GO:0010629 9.86 MIR132 MIR200B MIR21 MIR27A MIR27B MIR29C
4 negative regulation of angiogenesis GO:0016525 9.84 MIR200B MIR21 MIR29C MIR34A
5 positive regulation of angiogenesis GO:0045766 9.83 MIR132 MIR21 MIR27B MIR31 MIR378A
6 transforming growth factor beta receptor signaling pathway GO:0007179 9.82 MIR183 MIR21 MIR26A1
7 cholesterol homeostasis GO:0042632 9.81 MIR132 MIR27B MIR34A
8 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.78 MIR21 MIR26A1 MIR29C
9 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.77 MIR22 MIR26A1 MIR29C
10 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.73 MIR140 MIR26A1 MIR378A
11 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.72 MIR132 MIR21 MIR27B
12 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.72 MIR10B MIR132 MIR27A MIR27B MIR31
13 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 MIR21 MIR26A1 MIR27A MIR27B
14 negative regulation of vascular endothelial growth factor production GO:1904046 9.69 MIR140 MIR34A MIR378A
15 negative regulation of vascular endothelial cell proliferation GO:1905563 9.67 MIR132 MIR29C MIR34A
16 negative regulation of cholesterol efflux GO:0090370 9.67 MIR26A1 MIR27A MIR27B MIR33A
17 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.65 MIR21 MIR26A1
18 positive regulation of cellular senescence GO:2000774 9.65 MIR22 MIR34A
19 positive regulation of vascular endothelial cell proliferation GO:1905564 9.65 MIR132 MIR21 MIR27A
20 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.64 MIR27A MIR27B
21 negative regulation of nitric-oxide synthase activity GO:0051001 9.63 MIR132 MIR26A1
22 negative regulation of cell cycle G1/S phase transition GO:1902807 9.63 MIR26A1 MIR29C
23 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.63 MIR140 MIR21 MIR34A
24 positive regulation of smooth muscle cell differentiation GO:0051152 9.62 MIR22 MIR34A
25 negative regulation of vascular wound healing GO:0061044 9.61 MIR200B MIR34A
26 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.6 MIR21 MIR27A
27 regulation of cholesterol esterification GO:0010872 9.58 MIR27A MIR27B
28 negative regulation of monooxygenase activity GO:0032769 9.57 MIR27B MIR378A
29 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.55 MIR10B MIR132 MIR21 MIR27A MIR27B
30 gene silencing by miRNA GO:0035195 9.55 MIR378A MIR34A MIR33A MIR31 MIR29C MIR27B
31 negative regulation of lipid binding GO:1900131 9.52 MIR27A MIR27B
32 miRNA mediated inhibition of translation GO:0035278 9.5 MIR132 MIR200B MIR21 MIR27A MIR27B MIR31

Molecular functions related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.53 MIR378A MIR34A MIR33A MIR31 MIR29C MIR27B
2 RNA polymerase II complex binding GO:0000993 9.13 MIR378A MIR33A MIR140

Sources for Non-Alcoholic Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....